Phaseline

Targets › LAGE1

LAGE1 (Cancer/testis antigen 2): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Jul 2028.

Open in Phaseline: the race on LAGE1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
USWM CTletetresgene autoleucel (lete-cel, GSK3377794)
genetically engineered T cells targeting NY-ESO-1 (CTAG1B) and LAGE-1a
CTAG1B, LAGE1Phase 2NeoplasmsJul 2028

Conditions

Neoplasms (1)

Modalities

mixed (1)

Companies

USWM CT (1)

Related targets

CTAG1B (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.